Home Mechanical Ventilation in South Korea

Dong Hyun Kim,1 Seong-Woong Kang,2 and Won Ah Choi2
1Department of Rehabilitation Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul; 2Department of Rehabilitation Medicine, Gangnam Severance Hospital and Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Korea.

Received: May 23, 2013
Revised: February 25, 2014
Accepted: February 28, 2014
Corresponding author: Dr. Seong-Woong Kang, Department of Rehabilitation Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea. Tel: 82-2-2019-3490, Fax: 82-2-2019-3499 E-mail: kswoong@yuhs.ac

- The authors have no financial conflicts of interest.

Purpose: To survey the use of invasive and noninvasive home mechanical ventilation (HMV) methods in South Korea from the perspective of physical medicine and rehabilitation (PM&R).

Materials and Methods: For 413 users of HMV, retrospective reviews of PM&R interventions and survey of HMV methods employed from Mar 2000 to Dec 2009. Results: Of the 413 users, the majority of whom with progressive neuromuscular disorders (NMDs) (n=358), 284 patients initially used noninvasive mechanical ventilation (NIV), while 63 others who were using tracheostomy mechanical ventilation switched to NIV as part of their rehabilitation. The NMD patients began HMV at an earlier age (34.9±20.3 yrs), and used for longer (14.7±7.5) hours than patients with non-neuromuscular causes of respiratory impairment. Conclusion: Noninvasive management was preferred over invasive ones, and transition to the former was a result of PM&R interventions.

Key Words: Home mechanical ventilation, noninvasive mechanical ventilation, neuromuscular disease

INTRODUCTION

Advances in medical care have resulted in more patients requiring long-term home mechanical ventilation (HMV), and all too often results in ventilator users left with tracheostomy tubes without physical medicine and rehabilitation (PM&R) interventions.1 The cornerstone of PM&R intervention is pulmonary rehabilitation (PR). While most of the clinical care of pulmonary disease is limited to medical treatments, PR deals with a comprehensive intervention, based on a thorough patient assessment, followed by patient-tailored therapies, which include exercise training, education and behavioral changes designed to improve physical and psychological condition of people with chronic respiratory diseases.2 PR has long been directed to improving the medical and functional status of patients with parenchymal lung diseases such as chronic obstructive pulmonary disease,3 however, similar principles have generally been ignored for patients with neuromuscular diseases (NMDs). These measures can also be of value for patients with NMDs. In addition, the use of inspiratory and expiratory muscle aids, including noninvasive mechanical ventilation (NIV) and mechanically assisted coughing (MAC), can facilitate the decannulation of invasively managed ventilator users to more desirable
noninvasive aids.\textsuperscript{4}

Comprehensive surveys on HMV have been carried out in Europe, North America, Chile, and Japan,\textsuperscript{5} but not in Korea. Based on our previous 10 years of experience, therefore, we aimed to describe HMV and the role of PM&R in optimizing it.

**MATERIALS AND METHODS**

Patients with chronic respiratory failure requiring HMV were included in the study. We retrospectively reviewed their data from March 2000 when we first adopted systematized PM&R intervention to the HMV program at Gangnam Severance hospital until December 2009.

**The management status of patients with HMV**

The following parameters were investigated: basic demographic characteristics of all patients, causes of chronic respiratory dependence, type and mode of mechanical ventilator use, tracheostomy mechanical ventilation (TMV) vs. NIV use and any transition between them. We supplemented medical record reviews with telephone surveys of those with incomplete records or who had been lost to follow-up for over two years. For patients who were decannulated of their tracheostomy tubes, we analyzed the data before and after the decannulation. A follow-up survey was performed in October 2010 to explore any changes in HMV status.

**Pulmonary function evaluations**

1) Forced vital capacity (FVC) was measured in sitting and supine positions using a spirometer (Micro\textsuperscript{TM} spirometer; CareFusion 232 Ltd., Chatham, UK). The highest of 3 attempts was recorded as the FVC. We calculated predicted FVC values (FVC\textsubscript{pre}) based on age and height.\textsuperscript{6}

2) The maximal inspiratory pressure and maximal expiratory pressure measured in mouth in sitting position with an effort sustained for at least 1 second (MicroRPM; CareFusion 232 Ltd., Chatham, UK) to gauge inspiratory and expiratory muscle strength, respectively. The highest value of 3 or more attempts was used.

3) Peak cough flow (PCF) was measured by a peak flowmeter (ASSESS\textsuperscript{®}; Health Scan Products Inc., Cedar Grove, NJ, USA) with the patient coughing as hard as possible and the highest value of 3 or more attempts was recorded.

4) Assisted PCF (APCF) was measured by the same peak flow meter, but the inspiratory phase was augmented by the subjects air stacking,\textsuperscript{7} and the expiratory phase assisted by application of an abdominal thrust.\textsuperscript{8}

5) The ventilatory status was monitored by arterial blood gas analysis (ABGA) or by monitoring oxyhemoglobin saturation (SpO\textsubscript{2}) and end tidal carbon dioxide (EtCO\textsubscript{2}) via oximetry and capnometry (Microcap plus, Oridion Ltd., Jerusalem, Israel) just before HMV prescription, while using mechanical ventilation. For those who could not perform 1)-4) due to intubation or a tracheostomy tube as well as intolerance of breathing with the tube transiently capped for the measurement, the same test was performed after the decannulation or extubation.

Statistical analysis was made by SPSS 13.0 for windows version (SPSS Inc., Chicago, IL, USA), paired t-test was used to find the statistical significance between FVC in sitting and supine position in NMD groups, and Wilcoxon signed rank test was used for the comparison of non-NMD groups.

**Application of NIV**

When patients presented with subjective symptoms of hypventilation or when ventilatory abnormality was suspected from the result of a single daytime ABGA or EtCO\textsubscript{2} and SpO\textsubscript{2} measurement, overnight noninvasive monitoring was performed to detect latent hypercapnea. Initial NIV application was considered when patients showed elevated nocturnal EtCO\textsubscript{2} levels (>45 mm Hg) with or without multiple nocturnal SpO\textsubscript{2} below 95% on serial overnight monitoring. Nasal interfaces (Goldseal nasal mask, Respironics, Murrysvill, PA, USA) or oronasal interfaces (Performa Track\textsuperscript{TM} SE mask, Respironics, Murrysvill, PA, USA) were used for the transition from TMV to NIV. Candidates for decannulation and transition to NIV had the ability to attain APCF >160 L/min and had minimal or no dysphagia or dysarthria before intubation or tracheostomy. All TMV patients who fulfilled the above criteria without ongoing lung parenchymal lesions were included once for the transition training, and the decannulation processes were performed as previously described.\textsuperscript{9} Patients who could not follow commands or did not cooperate with training in NIV or with assist coughing were excluded from the consideration for decannulation.

**RESULTS**

The demographics and ventilator use characteristics of the patients are described in Table 1 and 2.
HMV in South Korea

Table 1. Basal Characteristics and Initial Mode of HMV in Progressive Neuromuscular Disease Patients

|                      | Myopathy (n=358) |                      |                      |
|----------------------|------------------|----------------------|----------------------|
|                      | DMD (n=113)      | ALS (n=141)          | SMA (n=25)           |
| Current age (yr)     | 23.5±5.5         | 33.0±17.8           | 59.3±11.3           |
| Age at ventilator application (yr) | 19.6±4.8         | 28.8±17.8           | 54.8±11.1           |
| Male/female          | 113/0            | 41/38                | 95/46               |
| TMV/NIV              | 11/102           | 19/60                | 38/103              |

HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation; DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy.

Table 2. Basal Characteristics and Initial Mode of HMV in Non-Neuromuscular Disease Patients

|                      | SCI (n=32)       | Cerebral diseases (n=10) | Miscellaneous (n=13) |
|----------------------|------------------|--------------------------|----------------------|
| Current age (yr)     | 48.0±17.9        | 46.8±20.2                | 48.9±17.1            |
| Age at ventilator application (yr) | 45.5±18.0        | 45.1±21.0                | 45.5±17.3            |
| Male/female          | 26/6             | 4/6                      | 7/6                  |
| TMV/NIV              | 30/2             | 9/1                      | 9/4                  |

HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation; SCI, spinal cord injury.

Pulmonary function evaluations

Of the 413 patients, we analyzed the data of 306 patients whose pulmonary function tests at initial HMV application were available (Table 3). The results of pulmonary function assessment were used to determine when and how HMV was used.

Methods of HMV

Of the 284 patients who initially used NIV, NMD accounted for the majority (97.5%). On the follow up, 233 patients were still using NIV, and of 46 patients who switched to TMV, 42 were amyotrophic lateral sclerosis (ALS) who could not tolerate NIV any further because of stridor occurring from upper airway spasticity and paralysis (Table 4). One spinal muscular atrophy (SMA) patient started nocturnal NIV, but underwent tracheostomy due to extubation failure after scoliosis surgery. After transition training of NIV, he succeeded in decannulation once again, and is using nocturnal NIV. One spinal cord injury (SCI) patient developed hypoxic brain injury, and 2 myopathy patients underwent emergency tracheostomies during respiratory arrests.

One hundred twenty-nine patients started HMV invasively; 121 were using TMV, and the other 8 patients were extubated to NIV (Table 5-1). Two major causes of transition failure to NIV were accompanying bulbar muscle weakness and insufficient cooperation due to either young age (<7 yrs old) or mental retardation (Table 5-2). Details of the 63 initial TMV users who succeeded in decannulation are described in Table 6-1 and 6-2, and flow diagram of HMV application by lapse of time is described in Fig. 1.

The most frequently prescribed mode of HMV was assisted controlled ventilation based on volume cycled systems. Although there were initially 42 bilevel positive airway pressure (BiPAP) and 3 continuous positive airway pressure users, all except for 4 patients [2 myotonic muscular dystrophy (MMD), 1 SMA and 1 cerebral disease] who were using BiPAP were switched to assist control mode ventilation on prescription. Major cause of the mode change was either unsatisfactory ventilation results or patients’ maladjustment to the preset modes.

At initial HMV application, 231 patients used nocturnal HMV, 125 patients used HMV nocturnally plus some daytime, and 57 patients required near full time HMV (≥22 hours). When the application time was reinvestigated in 2010, 16 patients no longer used HMV; 5 voluntarily quit the use of HMV against advice, 11 totally weaned off HMV. Changes of HMV dependent hours in each diagnostic group are described in Table 4 and 5.
Table 3. Results of Pulmonary Function Assessment

|                          | Myopathy          | ALS (n=95) | SMA (n=17) | SCI (n=22) | Cerebral diseases (n=4) | Miscellaneous (n=8) | Total (n=306) |
|--------------------------|-------------------|------------|------------|------------|------------------------|---------------------|---------------|
|                          |                   |            |            |            |                        |                     |               |
|                          |                   | DMD (n=100)| Others (n=60)|            |                        |                     |               |
| FVC<sub>sit</sub> (mL)   | 653.4±403.1       | 1017.1±644.9| 1143.6±290.5| 617.3±390.5| 709.5±322.1            | 1115.0±265.0       | 878.4±579.9  |
| p<sub>FVC<sub>sit</sub> (%) | 17.9±12.7        | 28.9±16.3*| 28.7±16.0| 22.5±12.5| 17.2±8.0*              | 33.0±12.1          | 28.7±8.1     |
| FVC<sub>sup</sub> (mL)   | 619.6±385.2       | 842.4±560.4| 966.0±531.2| 623.8±398.2| 810±326.3              | 1197.5±143.4       | 781.3±500.1  |
| p<sub>FVC<sub>sup</sub> (%) | 16.7±11.3        | 23.6±14.4*| 24.0±12.9| 22.2±11.7| 17.2±8.0              | 35.2±8.7           | 19.7±13.9    |
| PCF (L/min)              | 148.2±58.1        | 194.3±73.6| 184.0±77.2| 173.1±88.0| 124±18.2              | 170.0±127.3        | 161.2±83.1   |
| APCF (L/min)             | 267.1±164.3       | 340.7±344.0| 267.6±105.4| 194±98.2  | 207.9±75.2            | 190±84.9          | 235.0±60.6   |
| MIP (cmH<sub>2</sub>O)   | 18.0±10.4         | 26.4±14.4| 19.9±12.9| 26.0±18.5| 18.8±9.5              | 20.7±3.8           | 29.0±16.2    |
| MIP<sub>pre</sub> (%)    | 18.3±11.1         | 34.5±19.2| 25.6±16.8| 31.5±25.6| 23.5±13.5             | 27.8±1.8           | 36.0±15.3    |
| MEP (cmH<sub>2</sub>O)   | 18.4±9.8          | 34.9±20.6| 26.6±19.6| 24.6±19.6| 21.2±20.7             | 39.7±31.0          | 57.9±52.7    |
| MEP<sub>pre</sub> (%)    | 13.1±7.9          | 33.3±20.6| 23.1±16.2| 19.3±16.7| 19.2±22.9             | 35.1±18.2          | 48.1±35.4    |

DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy; SCI, spinal cord injury; FVC<sub>sit</sub>, forced vital capacity in sitting position; FVC<sub>sup</sub>, normal predicted value of FVC in sitting position; FVC<sub>sup</sub>, forced vital capacity in supine position; FVC<sub>sup</sub>, normal predicted value of FVC in supine position; PCF, peak cough flow; APCF, assisted peak cough flow; MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; MIP<sub>pre</sub>, normal predicted value of MIP; MEP<sub>pre</sub>, normal predicted value of MEP.

Miscellaneous: lung parenchymal disease (n=3), Guillain-Barre syndrome (n=4), central hypoalveolar syndrome (n=1), Down syndrome with obstructive sleep apnea (n=1), cor pulmonale due to kyphoscoliosis (n=2), myesthenia gravis (n=2). Values are mean±standard deviation.

*<i>p</i><0.05, comparison of preFVC<sub>sit</sub> and preFVC<sub>sup</sub> in other myopathy group.
†<i>p</i><0.05, comparison of preFVC<sub>sit</sub> and preFVC<sub>sup</sub> in ALS group.
‡<i>p</i><0.05, comparison of preFVC<sub>sit</sub> and preFVC<sub>sup</sub> in SCI group.

Table 4. Details of Initial NIV Users (n=284)

|                          | Myopathy          | ALS (n=103) | SMA (n=12) | SCI (n=2) | Cerebral diseases (n=1) | Miscellaneous (n=4) | Total (n=284) |
|--------------------------|-------------------|------------|------------|------------|------------------------|---------------------|---------------|
|                          |                   |            |            |            |                        |                     |               |
|                          |                   | DMD (n=102)| Others (n=60)|            |                        |                     |               |
| Initial HMV (hrs/day)    | 8.6±3.7           | 7.9±2.5   | 8.3±5.8   | 6.8±1.3   | 8.0±2.8               | 21                  | 7.8±1.0       | 8.3±4.4      |
| Follow-up HMV (hrs/day)  | 12.8±6.3          | 10.0±5.5  | 19.2±7.4  | 8.3±1.8   | 15.0±12.7             | 22                  | 6.0±4.1       | 13.9±7.4     |
| Regular PM&R intervention| 40                | 13        | 32         | 1          | 0                      | 0                   | 0              | 86           |
| Mode of HMV at follow-up; TMV/NIV/weaning | 1/100/1| 2/56/2| 42/60/1| 0/12/0| 1/1/0| 0/1/0| 0/3/1| 46/23/3/5 |

HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation; DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy; SCI, spinal cord injury; PM&R, physical medicine and rehabilitation.

Values are mean±standard deviation. Others: Becker’s muscular dystrophy (n=5), congenital myopathy (n=7), Emery-Dreifuss muscular dystrophy (n=2), fascioscapulohumeral dystrophy (n=5), limb-girdle muscular dystrophy (n=3), mitochondrial cytopathy (n=5), myotonic muscular dystrophy (n=10), non-specific progressive muscular dystrophy (n=18), inclusion body myositis (n=2), nemaline myopathy (n=1), Nonaka myopathy (n=1), polymyositis (n=1), Pompe’s disease (n=2), Swartz-Jampel syndrome (n=1), Miscellaneous: central hypoalveolar syndrome (n=1), cor pulmonale due to kyphoscoliosis (n=2), myesthenia gravis (n=1).
**Table 5-1. Details of Initial TMV Users (n=129)**

| Myopathy         | DMD (n=11) | Others (n=19) | ALS (n=38) | SMA (n=13) | SCI (n=30) | Cerebral diseases (n=9) | Miscellaneou... (n=9) | Total (n=129) |
|------------------|------------|---------------|------------|------------|------------|------------------------|-----------------------|---------------|
| Initial HMV (hrs/day) | 13.5±7.7   | 14.2±7.8      | 15.0±7.8   | 14.5±9.3   | 14.2±7.6   | 14.5±8.5               | 7.8±2.0               | 14.0±7.7      |
| Follow-up HMV (hrs/day) | 13.8±6.7   | 15.8±7.6      | 20.1±6.2   | 17.8±7.2   | 9.6±8.4    | 7.7±7.6               | 4.7±4.8               | 13.8±8.6      |
| Regular PM&R intervention | 0          | 0             | 9          | 1          | 0          | 0                      | 0                     | 10            |
| Mode of HMV at follow-up; TMV/NIV/weaning | 3/8/0      | 10/9/0        | 35/3/0     | 7/6/0      | 9/15/6     | 6/2/1                  | 1/4/4                 | 71/47/11      |

HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation; DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy; SCI, spinal cord injury; PM&R, physical medicine and rehabilitation.

Values are mean±standard deviation. Others: congenital myopathy (n=4), fascioscapulohumeral dystrophy (n=1), mitochondrial cytopathy (n=2), myotonic muscular dystrophy (n=3), nonspecific progressive muscular dystrophy (n=5), Klippel-Feil syndrome (n=1), critical illness myopathy (n=1), myotubular myopathy (n=1), Pompe’s disease (n=1). Miscellaneous: lung parenchymal disease (n=3) [s/p lung transplantation, bilateral phrenic N. palsy, tuberculosis destroyed lung], Guillain-Barre syndrome (n=4), Down syndrome with obstructive sleep apnea (n=1), myesthenia gravis (n=1).

**Table 5-2. Causes of Initial TMV Use (n=129)**

| Detailed reasons for initial TMV application | No. of patients |
|--------------------------------------------|-----------------|
| 1 Elective tracheostomy                    |                 |
| NIV failure due to bulbar symptoms and/or poor compliance | 21              |
| NIV failure due to young age, mental retardation or hypoxic brain injury | 4               |
| 2 Tracheostomy due to repeated extubation/weaning failure | 4               |
| 3 Admitted or transferred with tracheostomy state |                 |
| Failure in decannulation & maintenance of tracheostomy | 33              |
| Success in decannulation & switched to NIV | 55              |
| 4 Admitted or transferred with intubation   |                 |
| Failure in extubation & tracheostomy       | 4               |
| Success in extubation & switch to NIV      | 8               |

TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation.

**Management of patients with HMV**

Among the HMV users investigated, only 96 patients [ALS 41, Duchenne muscular dystrophy (DMD) 40, SMA 2, other myopathy 13] received regular PM&R interventions including serial pulmonary function evaluations and ventilation monitoring. Eighty-six patients from this group started NIV, and 10 initially used TMV. Of the 86 NIV users, 68 were maintaining NIV, but 18 (ALS 16, MMD 1, DMD 1) were switched to TMV during follow-up periods (Table 4 and 5-1). Nine initial TMV users, except 1 SMA who succeeded in decannulation, were still using TMV at the follow-up.

**DISCUSSION**

Although a few studies exist on the management status of ventilatory impairment in NMDs, the present study is the first report which contains detailed information of different disease groups in relation to HMV in Korea. Previous surveys revealed variations between countries in the proportion of lung and neuromuscular patients ventilated, preferred ventilator and interface types. Despite the advantages, ventilation via tracheostomy still accounts for the highest percentage in NMDs worldwide. Total number of progressive NMD patients is also high in this study. Improved availability to HMV since the introduction of a public subsidy for NMDs, and the characteristics of a center at which the survey was conducted may contribute to this.

PM&R intervention for patients with chronic respiratory failure mainly consists of regular monitoring of ventilation and pulmonary function, maintenance of pulmonary compliance, optimization of sputum clearance, and timely application as well as transition training to NIV. In the present study, only 96 patients received regular PM&R check-ups before the onset of subjective symptoms or overt respiratory failure occurred. Although 10 patients initially used TMV, 9 were severe bulbar ALS patients. In contrast, 62 of the decannulated patients (98.4%) did not benefit from early PM&R check-ups before developing respiratory failure. Although they finally succeeded in decannulation, patients could have avoided unnecessary invasive procedures which
aggressive use of continuous NIV and MAC can result in more favorable outcomes and better survival. A growing population of patients exist who have chronic respiratory failure due to conditions such as NMDs, SCI, or lung parenchymal disorders, and who require either tracheostomy or mask ventilation. However, the lack of concrete local guidelines and shortage of experienced physicians specialized in PM&R interventions are the main obstacles to extensively employ the management. Furthermore, the availability and practical details of complex respiratory support at home involve many variables.

Table 6-1. Details of the Decannulated Patients (n=63)

|                  | Myopathy | DMD (n=8) | ALS (n=5) | SMA (n=6) | SCI (n=22) | Cerebral diseases (n=3) | Miscellaneou (n=9) | Total (n=63) |
|------------------|----------|-----------|-----------|-----------|-----------|-------------------------|-------------------|-------------|
| Hrs/day of HMV at decannulation | 9.5±4.5  | 8.6±2.8   | 13.2±9.9 | 10.0±6.9 | 12.8±7.1 | 7.7±1.2                | 7.8±2.0          | 10.5±6.0    |
| Hrs/day of HMV at follow-up     | 12.1±4.9 | 11.5±6.1  | 19.7±7.5 | 12.8±6.2 | 5.4±1.1   | 4.7±4.0                | 4.7±4.8          | 8.7±6.5     |
| Mode of HMV at follow-up; TMV/NIV/weaning | 0/8/0 | 1/9/0     | 2/3/0    | 0/6/0    | 1/15/6 | 0/2/1                  | 1/4/4            | 5/47/11     |

HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation; DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; SMA, spinal muscular atrophy; SCI, spinal cord injury.

Table 6-2. Specific Transitions from Decannulation to TMV (n=5)

| No. of patients | Diagnosis                | Causes of transition to tracheostomy |
|-----------------|--------------------------|--------------------------------------|
| 1               | MMD                      | Sudden cardiac arrest                |
| 2               | ALS                      | End-stage illness                    |
| 1               | Tetraplegic SCI          | Sudden mucus plugging leading to hypoxic brain injury |
| 1               | Tuberculosis destroyed lung | Severe pneumonia                     |

TMV, tracheostomy mechanical ventilation; MMD, myotonic muscular dystrophy;ALS, amyotrophic lateral sclerosis; SCI, spinal cord injury.

Fig. 1. Flow diagram of HMV application. HMV, home mechanical ventilation; TMV, tracheostomy mechanical ventilation; NIV, noninvasive mechanical ventilation.

caused pain, increased medical costs and hospitalization if they had been optimally managed at the onset.

Of the 413 patients, 293 turned out to be alive at the follow-up in 2010, whereas 120 patients were either expired or presumed to be dead; 118 of them were NMDs (ALS 86, DMD 15, other myopathies 14, SMA 3), and 2 were non-NMD patients (1 SCI, 1 brain stem glioma). Specific causes of death were not fully investigated in this study. In spite of prolonged median survival of these patients, respiratory failure comprised the major cause of death to certain NMD patients, especially in ALS. As proven in recent literatures, aggressive use of continuous NIV and MAC can result in more favorable outcomes and better survival.

A growing population of patients exist who have chronic respiratory failure due to conditions such as NMDs, SCI, or lung parenchymal disorders, and who require either tracheostomy or mask ventilation. However, the lack of concrete local guidelines and shortage of experienced physicians specialized in PM&R interventions are the main obstacles to extensively employ the management. Furthermore, the availability and practical details of complex respiratory support at home involve many variables.
Even though this study includes a large number of HMV users, the results cannot fully reflect general status of Korea. Future collaboration with several district university hospitals will be necessary to expand the results.

In conclusion, a thorough understanding and application of PM&R interventions can be of value in improving the care and quality of life for patients with long-term HMV.

ACKNOWLEDGEMENTS

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2010 (6-2010-0025).

REFERENCES

1. Racca F, Berta G, Sequi M, Bignamini E, Capello E, Cutrera R, et al. Long-term home ventilation of children in Italy: a national survey. Pediatr Pulmonol 2011;46:566-72.
2. Spruit MA, Clini EM. Towards health benefits in chronic respiratory diseases: pulmonary rehabilitation. Eur Respir Rev 2013;22:202-4.
3. Hill NS. Pulmonary rehabilitation. Proc Am Thorac Soc 2006;3:66-74.
4. Bach JR, Gonçalves MR, Hon A, Ishikawa Y, De Vito EL, Prado F, et al. Changing trends in the management of end-stage neuromuscular respiratory muscle failure: recommendations of an international consensus. Am J Phys Med Rehabil 2013;92:267-77.
5. Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Faurox B, et al. Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J 2005;25:1025-31.
6. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971;103:57-67.
7. Kang SW, Bach JR. Maximum insufflation capacity. Chest 2000;118:61-5.
8. Lee SC, Park JH, Kang SW, Kim DH, Song SH. External control of exhalation for cough assistance: a method for patients with glottis dysfunction and/or tracheostomy. Arch Phys Med Rehabil 2009;90:1402-7.
9. Bach JR, Saporito LR. Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure. A different approach to weaning. Chest 1996;110:1566-71.
10. Kim DH, Kang SW, Choi W, Moon JH, Baek JH, Choi SH, et al. A research on the management of ventilatory insufficiency in patients with neuromuscular diseases. J Korean Acad Rehabil Med 2010;34:347-54.
11. Kang SW, Park JH, Ryu HH, Kang YS, Moon JH. Non-invasive mechanical ventilator care for the patients with advanced neuromuscular disease. J Korean Acad Rehabil Med 2004;28:71-7.
12. Dybwik K, Tøllås T, Nielsen EW, Brinchmann BS. Why does the provision of home mechanical ventilation vary so widely? Chron Respir Dis 2010;7:67-73.
13. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 1997;152 Suppl 1:S10-7.
14. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 2011;56:744-50.
15. Ishikawa K, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord 2011;21:47-51.